Mast Therapeutics (MSTX +16.2%) reports that its evaluation of strategic alternatives includes a possible reverse merger with a privately-held firm.
Growth Capitalist (https://growthcapitalist.com/2016/11/mast-therapeutics-mulling-reverse-merger-shares-up-16/)
Mast Therapeutics (MSTX +16.2%) reports that its evaluation of strategic alternatives includes a possible reverse merger with a privately-held firm.